[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

NO2303330T3 - - Google Patents

Info

Publication number
NO2303330T3
NO2303330T3 NO09758025A NO09758025A NO2303330T3 NO 2303330 T3 NO2303330 T3 NO 2303330T3 NO 09758025 A NO09758025 A NO 09758025A NO 09758025 A NO09758025 A NO 09758025A NO 2303330 T3 NO2303330 T3 NO 2303330T3
Authority
NO
Norway
Application number
NO09758025A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41051156&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2303330(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2303330T3 publication Critical patent/NO2303330T3/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO09758025A 2008-06-06 2009-06-07 NO2303330T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5932608P 2008-06-06 2008-06-06
PCT/IL2009/000567 WO2009147681A1 (en) 2008-06-06 2009-06-07 Pharmaceutical compositions for treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
NO2303330T3 true NO2303330T3 (pl) 2018-04-14

Family

ID=41051156

Family Applications (1)

Application Number Title Priority Date Filing Date
NO09758025A NO2303330T3 (pl) 2008-06-06 2009-06-07

Country Status (22)

Country Link
US (2) US8969417B2 (pl)
EP (1) EP2303330B2 (pl)
JP (1) JP5648216B2 (pl)
KR (1) KR101613749B1 (pl)
CN (1) CN102105169B (pl)
AU (1) AU2009254730B2 (pl)
BR (1) BRPI0914902B8 (pl)
CA (1) CA2726833C (pl)
CL (1) CL2010001358A1 (pl)
CY (1) CY1119865T1 (pl)
DK (1) DK2303330T4 (pl)
ES (1) ES2659394T5 (pl)
HU (1) HUE037974T2 (pl)
LT (1) LT2303330T (pl)
MX (1) MX2010013393A (pl)
NO (1) NO2303330T3 (pl)
NZ (1) NZ590291A (pl)
PL (1) PL2303330T5 (pl)
PT (1) PT2303330T (pl)
RU (1) RU2540470C9 (pl)
WO (1) WO2009147681A1 (pl)
ZA (1) ZA201100034B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58988B1 (sr) 2010-02-03 2019-08-30 Pharma Two B Ltd Formulacije razagilina sa produženim oslobađanjem i njegove upotrebe
TW201304822A (zh) * 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
US9504657B2 (en) * 2012-01-12 2016-11-29 Pharmatwob Ltd. Fixed dose combination therapy of Parkinson's disease
LT2802319T (lt) * 2012-01-12 2018-04-10 Pharma Two B Ltd. Fiksuotos dozės derinio terapija, skirta parkinsono ligai gydyti
WO2013168032A1 (en) * 2012-05-07 2013-11-14 Micro Labs Limited Pharmaceutical compositions comprising rasagiline
KR101320945B1 (ko) * 2012-07-03 2013-10-23 주식회사파마킹 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제
EP2900226A4 (en) * 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
BR112015022896B1 (pt) 2013-03-15 2022-08-23 Chongxi Yu Composto de fármacos de alta penetração, composição farmacêutica e seus usos para o tratamento de doenças de parkinson
EP2808023A1 (en) * 2013-05-30 2014-12-03 Université Pierre et Marie Curie (Paris 6) New drug for the treatment and/or prevention of depressive disorders
CN104473942A (zh) * 2014-12-12 2015-04-01 青岛大学 一种抗帕金森氏病的药物组合物
ES2869981T3 (es) 2015-05-26 2021-10-26 Technophage Investig E Desenvolvimento Em Biotecnologia Sa Composiciones para su uso en el tratamiento de la enfermedad de parkinson y trastornos relacionados
WO2017070293A1 (en) * 2015-10-20 2017-04-27 Ironwood Pharmaceuticals, Inc. Phosphodiesterase 9 inhibitor and levodopa therapy
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
CN110325214A (zh) * 2016-12-22 2019-10-11 Rvx疗法有限公司 用于预防和治疗神经元损伤的低剂量药物组合
WO2019010491A1 (en) * 2017-07-07 2019-01-10 University Of Pittsburgh-Of The Commonwealth System Of Higher Education COMBINATIONS OF MEDICINES FOR THE PROTECTION AGAINST THE DEATH OF NEURONAL CELLS
JP6596483B2 (ja) * 2017-12-28 2019-10-23 テックフィールズ ファーマ カンパニー リミテッド パ−キンソン病治療用の新規高透過薬物及びその組成物
WO2020084168A1 (en) * 2018-10-26 2020-04-30 Icm (Institut Du Cerveau Et De La Moelle Épinière) Tetracycline compound for treating drug-induced dyskinesia
CN113924086A (zh) * 2019-04-17 2022-01-11 维奇健康科学有限责任公司 液体药物组合物
EP3946302A4 (en) * 2019-05-09 2023-01-04 Apkarian Technologies LLC METHODS AND COMPOSITIONS FOR PAIN MANAGEMENT
CN112915083A (zh) 2019-12-06 2021-06-08 上海医药集团股份有限公司 药物组合物、成套药盒及其应用
US11896573B2 (en) 2020-07-24 2024-02-13 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
US12084491B2 (en) 2020-09-10 2024-09-10 Prothena Biosciences Limited Treatment of Parkinson's disease
WO2022076466A1 (en) 2020-10-05 2022-04-14 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
CN114762684B (zh) * 2021-01-14 2023-11-21 华益泰康药业股份有限公司 一种治疗帕金森的缓释胶囊及其制备方法
EP4308086A1 (en) 2021-03-19 2024-01-24 XWPharma Ltd. Pharmacokinetics of combined release formulations of a gamma-hydroxybutyric acid derivative
KR20240080457A (ko) * 2022-11-30 2024-06-07 주식회사한국파마 신경퇴행성 질환 예방 또는 치료용 필름코팅정제

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3764144D1 (de) † 1986-04-16 1990-09-13 Asta Pharma Ag Synergistische kombination von amantadin und selegilin.
US5190763A (en) * 1990-05-07 1993-03-02 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
US5221536A (en) * 1990-05-07 1993-06-22 Alza Corporation Dosage form indicated for the management of abnormal posture, tremor and involuntary movement
PT828513E (pt) * 1995-05-26 2004-05-31 Pfizer Combinacoes contendo antagonistas selectivos de nmda para o tratamento do parkinsonismo
CA2407031A1 (en) 2000-04-19 2001-10-25 Lilly Icos Llc Use of cyclic gmp-specific phosphodiesterase inhibitors for treatment of parkinson's disease
US20070225379A1 (en) * 2001-08-03 2007-09-27 Carrara Dario Norberto R Transdermal delivery of systemically active central nervous system drugs
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
JP2007523122A (ja) 2004-02-20 2007-08-16 ノバルティス アクチエンゲゼルシャフト 神経変性障害および認知障害の処置のためのｄｐｐ−ｉｖ阻害剤
CA2613107A1 (en) 2005-06-23 2007-01-04 Spherics, Inc. Delayed release or extended-delayed release dosage forms of pramipexole
WO2007048034A2 (en) 2005-10-21 2007-04-26 Caritas St. Elizabeth Medical Center Of Boston, Inc. Use of androgens for the treatment of parkinson' s disease
DE602006018529D1 (de) 2005-12-29 2011-01-05 Osmotica Kereskedelmi Es Szolgaltato Kft Mehrschichtige tablette mit dreifacher freisetzungskombination
WO2007093450A2 (en) 2006-02-17 2007-08-23 Birds Pharma Gmbh Berolina Innovative Research & Development Services Deuterated catecholamine derivatives and medicaments comprising said compounds
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP2026803B1 (en) 2006-05-16 2011-12-21 Knopp Neurosciences, Inc. Compositions of r(+) and s(-) pramipexole and methods of using the same
EP2040698A4 (en) 2006-07-14 2011-08-10 Shionogi & Co OXIM CONNECTIONS AND ITS USE
US7531572B2 (en) 2006-07-28 2009-05-12 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs of α-amino acids, methods of synthesis and use
ATE510538T1 (de) 2006-08-11 2011-06-15 Univ Johns Hopkins Zusammensetzungen und verfahren für nervenschutz
EP2069300A2 (en) 2006-08-21 2009-06-17 Prexa Pharmaceuticals, Inc. Multimediator transporter inhibitors for use in treatment of central nervous system disorders
US7622495B2 (en) 2006-10-03 2009-11-24 Neurim Pharmaceuticals (1991) Ltd. Substituted aryl-indole compounds and their kynurenine/kynuramine-like metabolites as therapeutic agents
ES2433118T3 (es) 2006-11-01 2013-12-09 Purdue Pharma Lp Compuestos de fenilpropionamida y uso de los mismos
JP2010525018A (ja) † 2007-04-24 2010-07-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング プラミペキソール又はその医薬的に許容できる塩を含有する徐放性錠剤型製剤との組成物

Also Published As

Publication number Publication date
JP2011522035A (ja) 2011-07-28
PL2303330T3 (pl) 2018-04-30
AU2009254730A1 (en) 2009-12-10
MX2010013393A (es) 2011-06-21
ZA201100034B (en) 2012-04-25
US8969417B2 (en) 2015-03-03
PL2303330T5 (pl) 2021-10-25
EP2303330A1 (en) 2011-04-06
RU2540470C2 (ru) 2015-02-10
BRPI0914902B8 (pt) 2022-04-12
ES2659394T3 (es) 2018-03-15
EP2303330B1 (en) 2017-11-15
CA2726833A1 (en) 2009-12-10
KR101613749B1 (ko) 2016-04-19
DK2303330T4 (da) 2021-09-13
ES2659394T5 (es) 2021-12-13
HUE037974T2 (hu) 2018-09-28
JP5648216B2 (ja) 2015-01-07
US20110230513A1 (en) 2011-09-22
NZ590291A (en) 2013-11-29
WO2009147681A1 (en) 2009-12-10
BRPI0914902B1 (pt) 2022-02-22
CY1119865T1 (el) 2018-06-27
AU2009254730B2 (en) 2014-06-26
CN102105169A (zh) 2011-06-22
RU2540470C9 (ru) 2015-07-20
DK2303330T3 (en) 2018-02-26
CL2010001358A1 (es) 2011-08-19
KR20110031181A (ko) 2011-03-24
BRPI0914902A2 (pt) 2017-06-20
CN102105169B (zh) 2014-09-10
EP2303330B2 (en) 2021-06-16
US9259418B2 (en) 2016-02-16
US20150133513A1 (en) 2015-05-14
CA2726833C (en) 2016-03-22
LT2303330T (lt) 2018-04-10
PT2303330T (pt) 2018-02-12
RU2010154716A (ru) 2012-08-10

Similar Documents

Publication Publication Date Title
BR112016019572A2 (pl)
BRPI0909040A2 (pl)
BRPI0917573A2 (pl)
BRPI0908549B8 (pl)
BRPI0918697A2 (pl)
BRPI0917525A2 (pl)
BRPI0920750A2 (pl)
BRPI0919470A2 (pl)
BRPI0922455A2 (pl)
BRPI0907698A2 (pl)
BRPI0917618A8 (pl)
BRPI0912727A2 (pl)
BRPI0923734A2 (pl)
BRPI0908285A2 (pl)
BRPI0922669A2 (pl)
BRPI0910485A2 (pl)
BRPI0914750A2 (pl)
BRPI0908120A2 (pl)
BRPI0904541A8 (pl)
BRPI0912462A2 (pl)
BRPI0919811A2 (pl)
BRPI0915616A2 (pl)
BRPI0920914A2 (pl)
NO2303330T3 (pl)
BRPI0922550A2 (pl)